Pseudotyped Δ-G/SARS-CoV-2-S_D614Gd21-NLucP rVSV
rVSVΔG/SARS-CoV-2-S-D614Gd21-NLucP is a recombinant vesicular stomatitis virus in which the native glycoprotein has been replaced with the SARS-CoV-2 Spike protein.
Highlights:
- For better incorporation, the Spike protein lacks the last 21 residues of the cytoplasmic tail and contains the D614G amino acid change
- Virus interacts and enters cells through the SARS-CoV-2 Spike, but once fusion has occurred, replicates using the VSV machinery
- Virus also encodes nano-luciferasePEST to enable easy quantification of viral replication
- Supplied virus has been passaged two times on Vero cells after the original recovery from the molecular clone
It is the responsibility of the principal investigator to seek Institutional Biosafety Safety Committee approval for recombinant DNA, transgenic animal or infectious agent use within their laboratory spaces and maintain an Institutional Biosafety Safety Committee approval during the time period these materials are used.
From the laboratory of Melinda A. Brindley, PhD, University of Georgia.
rVSVΔG/SARS-CoV-2-S-D614Gd21-NLucP is a recombinant vesicular stomatitis virus in which the native glycoprotein has been replaced with the SARS-CoV-2 Spike protein.
Highlights:
- For better incorporation, the Spike protein lacks the last 21 residues of the cytoplasmic tail and contains the D614G amino acid change
- Virus interacts and enters cells through the SARS-CoV-2 Spike, but once fusion has occurred, replicates using the VSV machinery
- Virus also encodes nano-luciferasePEST to enable easy quantification of viral replication
- Supplied virus has been passaged two times on Vero cells after the original recovery from the molecular clone
It is the responsibility of the principal investigator to seek Institutional Biosafety Safety Committee approval for recombinant DNA, transgenic animal or infectious agent use within their laboratory spaces and maintain an Institutional Biosafety Safety Committee approval during the time period these materials are used.
From the laboratory of Melinda A. Brindley, PhD, University of Georgia.
REQUIREMENTS
US customers - The USDA APHIS VS 16-6 or 16-6A permit must be obtained and a copy of the permit must be sent to Kerafast here, in advance of shipment. The Application Form VS 16-3 (Import controlled material import or transport organisms or vectors) must be submitted to USDA APHIS Veterinary Services to obtain the VS 16-6 or 16-6A permit.
Non-US customers - A BIS permit will be required in order to ship this product. Purchase restricted to End Users only. Please Contact Us for more information
| Product Type: | Virus |
| Biosafety Level: | BSL2 |
| Vector Information: | Virus was generated by transfecting the recombinant pVSV-d-G/ SARS-CoV-2-S_D614Gd21-NLucP plasmid along with VSV N, P, and L into BHK-T7 cells. Virus was then amplified on Vero cells. The virus encodes nano-luciferase-PEST (NLucP) which enables viral replication to be monitored with luciferase assays. The NLucP is not secreted, so cell lysates should be monitored. |
| Virus: | Recombinant vesicular stomatitis virus (rVSV) |
| Titer: | 10^6 TCID50U/mL on Vero cells |
| Serotype: | VSV Indiana/SARS-CoV-2 Wuhan strain |
| Inoculation Conditions: | Produce stocks at low MOI (0.01) and harvest when >80% of the culture shows signs of cytopathic effect |
| Storage: | -80C |
| Shipped: | Dry Ice |
- Havranek KE, Jimenez AR, Acciani MD, Lay Mendoza MF, Reyes Ballista JM, Diaz DA, Brindley MA. SARS-CoV-2 Spike Alternations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus. Viruses. 2020 Dec 18; 12(12). PMID: 33353101
If you publish research with this product, please let us know so we can cite your paper.
